Junshi Biotech announced that the company is carrying out a phase III clinical study of JS203 combined with chemotherapy to treat recurrent or refractory diffuse large B-cell lymphoma with bilituximab combined with chemotherapy. Recently, the first patient administration was completed. The study plans to enroll 282 participants and is the first registered clinical study for JS203.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.